Form 4: DiaMedica Director Acquires Shares via DSU Settlement

DiaMedica Therapeutics Director Randall Michael Giuffre acquired 6,175 shares of common stock through a deferred stock unit settlement, part of a pre-arranged plan.

Summary

• Randall Michael Giuffre, a Director of DiaMedica Therapeutics Inc. (DMAC), acquired 6,175 shares of common stock.
• The transaction occurred on January 2, 2026, at a price of $8.42 per share.
• These shares are issuable upon the settlement of deferred stock units (DSUs) granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan.
• The DSUs were granted in lieu of cash retainer fees totaling $52,000.
• The deferred stock units are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026.
• Following this transaction, Mr. Giuffre directly beneficially owns 398,587 shares of common stock.
• Additionally, Mr. Giuffre indirectly beneficially owns 25,573 shares through 424822 Albert Ltd, where he has sole voting and dispositive power, and 21,070 shares indirectly through his spouse.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even if compensation-related and pre-planned, generally reflects a positive signal of insider confidence in the company's long-term value. It increases the director's alignment with shareholder interests.

Positives

• A Director increasing their beneficial ownership in the company can signal confidence in the company's future prospects.
• The acquisition is part of a pre-arranged plan (Rule 10b5-1(c)), indicating a structured approach to compensation and share acquisition.

Future Outlook

The acquired deferred stock units are scheduled to vest in four equal installments throughout 2026, specifically on March 31, June 30, September 30, and December 31, indicating a future increase in directly held shares upon vesting.

Industry Context

This filing reflects a routine insider transaction related to director compensation, which is a common practice across various industries for aligning management and director interests with shareholders. It does not provide specific insights into broader industry trends or competitive landscape beyond the company's internal compensation structure.

Corporate Governance

Related Party Transactions

• The grant of deferred stock units to Director Randall Michael Giuffre in lieu of cash retainer fees constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling management's confidence and aligning their interests with long-term shareholder value.
• Employees: No direct impact mentioned, but the use of an omnibus incentive plan for directors could reflect broader compensation strategies.

Next Steps

• The deferred stock units will vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026.

Key Dates

Keywords

DiaMedica Therapeutics, DMAC, Insider Transaction, Form 4, Director Stock Acquisition, Deferred Stock Units, Equity Compensation, Rule 10b5-1